Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Review Special Issue Series: New Advances in Cardiovascular Medicine
share announcement

Review Special Issue Series: New Advances in Cardiovascular Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 25 June 2024 | Viewed by 5132

Special Issue Editor

Dr. Rita Pavasini

E-Mail Website
Guest Editor
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy
Interests: myocardial infarction; heart failure; cardiovascular disease; cardiovascular medicine; hypertension; atherosclerosis; echocardiography; valvular heart disease; endocarditis; cardio-oncology

Special Issue Information

Dear Colleagues,

In recent years there have been numerous advances in cardiology that have changed the way of conceiving the disease and the cardiopathic patient. Among these we cannot fail to include the advent of trans-catheter aortic valve implantation (TAVI) and, in general, structural heart interventions; the improvement of imaging techniques with the preponderant advancement of cardiac magnetic resonance (CMR) and computerized tomography (CT) in the non-invasive diagnosis of ischemic heart disease or cardiomyopathies, passing through new pacing techniques and ablative approaches; the use of artificial intelligence in the diagnosis of cardiovascular disease and new therapeutic approaches for heart failure. For this reason, the Journal of Clinical Medicine is pleased to announce a Special Issue entitled "Review Special Issue Series: New Advances in Cardiovascular Medicine". Narrative or systematic literature reviews will be accepted. The aim of this Special Issue is to provide complete updates relating to the new frontiers of cardiology.

Dr. Rita Pavasini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myocardial infarction
  • heart failure
  • valvular heart disease
  • echocardiography
  • multimodality imaging
  • pacing
  • arrythmias
  • endocarditis
  • artificial intelligence

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

10 pages, 3829 KiB  
Review
Coronary Plaque in Athletes
by Elisabetta Tonet, Matteo Arzenton, Marco De Pietri, Luca Canovi, Davide Lapolla, Alberto Sarti, Veronica Amantea, Andrea Raisi, Gianni Mazzoni, Gianluca Campo and Giovanni Grazzi
J. Clin. Med. 2024, 13(7), 2044; https://doi.org/10.3390/jcm13072044 - 01 Apr 2024
Viewed by 951
Abstract
The relationship between vigorous physical activity (PA) and the development of coronary atherosclerosis has remained less explored for many years. Recently, literature data have focused on coronary atherosclerosis in athletes showing that prevalence is not trivial, that there are differences among various types [...] Read more.
The relationship between vigorous physical activity (PA) and the development of coronary atherosclerosis has remained less explored for many years. Recently, literature data have focused on coronary atherosclerosis in athletes showing that prevalence is not trivial, that there are differences among various types of sport, and that there are some peculiar features. As a matter of fact, plaque composition in athletes seems to be characterized by calcium rather than soft components. Specific mechanisms through which vigorous PA influences coronary artery disease are not yet fully understood. However, the prevalent calcific nature of coronary plaques in athletes could be related with a trend in a lower cardiovascular event rate. Full article
(This article belongs to the Special Issue Review Special Issue Series: New Advances in Cardiovascular Medicine)
►▼ Show Figures

Figure 1

16 pages, 830 KiB  
Review
The Impact of Climate Change and Extreme Weather Conditions on Cardiovascular Health and Acute Cardiovascular Diseases
by Antonio De Vita, Antonietta Belmusto, Federico Di Perna, Saverio Tremamunno, Giuseppe De Matteis, Francesco Franceschi and Marcello Covino
J. Clin. Med. 2024, 13(3), 759; https://doi.org/10.3390/jcm13030759 - 28 Jan 2024
Viewed by 2531
Abstract
Climate change is widely recognized as one of the most significant challenges facing our planet and human civilization. Human activities such as the burning of fossil fuels, deforestation, and industrial processes release greenhouse gases into the atmosphere, leading to a warming of the [...] Read more.
Climate change is widely recognized as one of the most significant challenges facing our planet and human civilization. Human activities such as the burning of fossil fuels, deforestation, and industrial processes release greenhouse gases into the atmosphere, leading to a warming of the Earth’s climate. The relationship between climate change and cardiovascular (CV) health, mediated by air pollution and increased ambient temperatures, is complex and very heterogeneous. The main mechanisms underlying the pathogenesis of CV disease at extreme temperatures involve several regulatory pathways, including temperature-sympathetic reactivity, the cold-activated renin-angiotensin system, dehydration, extreme temperature-induced electrolyte imbalances, and heat stroke-induced systemic inflammatory responses. The interplay of these mechanisms may vary based on individual factors, environmental conditions, and an overall health background. The net outcome is a significant increase in CV mortality and a higher incidence of hypertension, type II diabetes mellitus, acute myocardial infarction (AMI), heart failure, and cardiac arrhythmias. Patients with pre-existing CV disorders may be more vulnerable to the effects of global warming and extreme temperatures. There is an urgent need for a comprehensive intervention that spans from the individual level to a systemic or global approach to effectively address this existential problem. Future programs aimed at reducing CV and environmental burdens should require cross-disciplinary collaboration involving physicians, researchers, public health workers, political scientists, legislators, and national leaders to mitigate the effects of climate change. Full article
(This article belongs to the Special Issue Review Special Issue Series: New Advances in Cardiovascular Medicine)
►▼ Show Figures

Figure 1

12 pages, 2346 KiB  
Review
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by Federica Frascaro, Nicola Bianchi, Federico Sanguettoli, Federico Marchini, Sofia Meossi, Luca Zanarelli, Elisabetta Tonet, Matteo Serenelli, Gabriele Guardigli, Gianluca Campo, Luana Calabrò and Rita Pavasini
J. Clin. Med. 2023, 12(24), 7737; https://doi.org/10.3390/jcm12247737 - 17 Dec 2023
Viewed by 1411
Abstract
Immune checkpoint molecules like cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), play a critical role in regulating the immune response, and immune checkpoint inhibitors (ICIs) targeting these checkpoints have shown clinical [...] Read more.
Immune checkpoint molecules like cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), play a critical role in regulating the immune response, and immune checkpoint inhibitors (ICIs) targeting these checkpoints have shown clinical efficacy in cancer treatment; however, their use is associated with immune-related adverse events (irAEs), including cardiac complications. The prevalence of cardiac irAEs, particularly myocarditis, is relatively low, but they can become a severe and potentially life-threatening condition, usually occurring shortly after initiating ICI treatment; moreover, diagnosing ICI-related myocarditis can be challenging. Diagnostic tools include serum cardiac biomarkers, electrocardiography (ECG), echocardiography, cardiac magnetic resonance (CMR) and endomyocardial biopsy (EMB). The treatment of ICI-induced myocarditis involves high-dose corticosteroids, which have been shown to reduce the risk of major adverse cardiac events (MACE). In refractory cases, second-line immunosuppressive drugs may be considered, although their effectiveness is based on limited data. The mortality rates of ICI-induced myocarditis, particularly in severe cases, are high (38–46%). Therapy rechallenge after myocarditis is associated with a risk of recurrence and severe complications. The decision to rechallenge should be made on a case-by-case basis, involving a multidisciplinary team of cardiologists and oncologists. Further research and guidance are needed to optimize the management of cancer patients who have experienced such complications, evaluating the risks and benefits of therapy rechallenge. The purpose of this review is to summarize the available evidence on cardiovascular complications from ICI therapy, with a particular focus on myocarditis and, specifically, the rechallenge of immunotherapy after a cardiac adverse event. Full article
(This article belongs to the Special Issue Review Special Issue Series: New Advances in Cardiovascular Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop